CRISPR Therapeutics

CRSP

Market cap $5.22B

Crispr Therapeutics remains highly volatile, disconnected from near-term fundamentals, yet I see long-term value far above current levels. CRSP's business progress is slow, with pipeline milestones and cash runway—not quarterly EPS—being the most relevant metrics for investors. Key risks include the commercial ramp of Casgevy, pipeline execution, and surviving cash burn until anticipated profitability in 2028.

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

CRISPR Therapeutics AG (CRSP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has three promising candidates in early development as well as its only approved product, Casgevy.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY ® launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading gene-editing and siRNA platforms across cardiovascular, autoimmune, oncology and rare diseases- -Starting 2026 with a strong balance sheet with approximately $2 billion in cash, cash equivalents, and marketable securities- ZUG, Switzerland and BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated 2026 milestones. "Entering 2026, CRISPR Therapeutics is well positioned, with CASGEVY® gaining momentum, and multiple programs with encouraging data advancing rapidly through clinical trials across a diverse set of therapeutic areas,” said Samarth Kulkarni, Ph.D.

CRISPR Therapeutics AG (CRSP) closed at $53.84 in the latest trading session, marking a -4.54% move from the prior day.

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.16, representing a +2.58% change from its previous close.

ZUG, Switzerland and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m.

Crispr Therapeutics AG commands a $5bn valuation, anchored by Casgevy's commercial approval and robust clinical data in SCD and TDT. Casgevy's slow commercial ramp is expected to accelerate in 2026, with revenue and patient growth as key valuation drivers. CRSP's pipeline—spanning in-vivo, CAR-T, and diabetes assets—offers major upside, but Casgevy remains the only revenue source.